Patent classifications
A61K47/52
MAGNETIC PARTICLE CONJUGATES, MICELLES, AND METHODS OF DELIVERING AGENTS
Embodiments of the present disclosure provide for magnetic particle conjugates, methods of making the magnetic particle conjugates, methods of using magnetic particle conjugates, micelles (also referred to as a “magnetic composite nanocarrier” (MCNC)), methods of making micelles, methods of using micelles, and the like.
MAGNETIC PARTICLE CONJUGATES, MICELLES, AND METHODS OF DELIVERING AGENTS
Embodiments of the present disclosure provide for magnetic particle conjugates, methods of making the magnetic particle conjugates, methods of using magnetic particle conjugates, micelles (also referred to as a “magnetic composite nanocarrier” (MCNC)), methods of making micelles, methods of using micelles, and the like.
COMPLEXES AND COMPOSITIONS COMPRISING PROBUCOL AND USES THEREOF
The present invention relates to complexes comprising probucol or derivatives thereof and mesoporous silica, methods for producing such complexes and uses thereof. The present invention also relates to uses of the complexes in the treatment of inflammation- and oxidation-related diseases and disorders.
COMPLEXES AND COMPOSITIONS COMPRISING PROBUCOL AND USES THEREOF
The present invention relates to complexes comprising probucol or derivatives thereof and mesoporous silica, methods for producing such complexes and uses thereof. The present invention also relates to uses of the complexes in the treatment of inflammation- and oxidation-related diseases and disorders.
SELF-ASSEMBLED COMPLEX BASED ON THE BODY SUBSTANCE CAPABLE OF CONTROLLING EFFECTIVE COMPONENT DELIVERY RATE THROUGH REVERSIBLE SELF-ASSEMBLY AND SELF-DISASSEMBLY AND EFFECTIVE COMPONENT DELIVERY SYSTEM USING THE SAME
The present invention relates to an effective component delivery system using self-assembly and self-disassembly of a self-assembled complex, and the effective component delivery system uses a self-assembled complex which is composed of substances existing in the body, thereby being less toxic and harmless to the human body, and the effective component delivery system is capable of controlling a self-disassembly rate and an effective component release rate by using various kinds of metal ions and ligands including phosphate or phosphonate.
IRON/SHIKONIN NANO-COMPOSITE AND USE THEREOF AND METHOD FOR PREPARING THE SAME BY SUPERMOLECULAR SELF-ASSEMBLY
An iron/shikonin nano-composite and a use thereof, and a method for preparing the same by supermolecular self-assembly, belonging to the technical field of functional materials. The composite consists of shikonin and ferric ions, wherein shikonin is coordinated with the ferric ions, and the hydroxyl and carbonyl groups in shikonin are coordinated with the ferric irons to form a complex, which is then assembled by π-π stacking and hydrophobic interactions to form a nano-composite which exhibits glutathione response. The composite is obtained by the following steps: adding an aqueous solution of a ferric salt and an organic solvent solution of shikonin in sequence into water while stirring at ambient temperature, continuously stirring at ambient temperature, and centrifuging the resulting mixture to purify, thereby obtaining an iron/shikonin nano-composite in the resulting solution.
IRON/SHIKONIN NANO-COMPOSITE AND USE THEREOF AND METHOD FOR PREPARING THE SAME BY SUPERMOLECULAR SELF-ASSEMBLY
An iron/shikonin nano-composite and a use thereof, and a method for preparing the same by supermolecular self-assembly, belonging to the technical field of functional materials. The composite consists of shikonin and ferric ions, wherein shikonin is coordinated with the ferric ions, and the hydroxyl and carbonyl groups in shikonin are coordinated with the ferric irons to form a complex, which is then assembled by π-π stacking and hydrophobic interactions to form a nano-composite which exhibits glutathione response. The composite is obtained by the following steps: adding an aqueous solution of a ferric salt and an organic solvent solution of shikonin in sequence into water while stirring at ambient temperature, continuously stirring at ambient temperature, and centrifuging the resulting mixture to purify, thereby obtaining an iron/shikonin nano-composite in the resulting solution.
MAGNETIC IMMUNO-PARTICLE AND USE THEREOF
Provided are magnetic immunoparticles and use thereof, specifically, magnetic immunoparticles including a cell membrane capable of capturing a pathogenic material and magnetic particles attached to the cell membrane, a method of detecting pathogenic materials using the magnetic immunoparticles, and a method of diagnosing and treating an infectious disease using the magnetic immunoparticles. The magnetic immunoparticles according to an aspect may include cell membranes capable of capturing pathogenic materials, and thus may minimize side effects in vivo, and may detect various kinds of pathogenic materials due to characteristics of the cells from which the cell membranes are derived. Further, since the magnetic immunoparticles include magnetic particles, the magnetic immunoparticles may be easily separated by applying a magnetic field, and thus pathogenic materials may be more effectively detected and removed.
MAGNETIC IMMUNO-PARTICLE AND USE THEREOF
Provided are magnetic immunoparticles and use thereof, specifically, magnetic immunoparticles including a cell membrane capable of capturing a pathogenic material and magnetic particles attached to the cell membrane, a method of detecting pathogenic materials using the magnetic immunoparticles, and a method of diagnosing and treating an infectious disease using the magnetic immunoparticles. The magnetic immunoparticles according to an aspect may include cell membranes capable of capturing pathogenic materials, and thus may minimize side effects in vivo, and may detect various kinds of pathogenic materials due to characteristics of the cells from which the cell membranes are derived. Further, since the magnetic immunoparticles include magnetic particles, the magnetic immunoparticles may be easily separated by applying a magnetic field, and thus pathogenic materials may be more effectively detected and removed.
FORMULATION OF NANOANTIBODY BASED DRUGS AND A METHOD FOR TREATING THROMBOTIC THROMBOCYTOPENIC PURPURA BY INHALATION
The present invention relates to stable formulations of a solution of nanoantibody drug that is suitable for inhalation and a method of treating acquired thrombotic thrombocytopenic purpura by administering the drug by inhalation using a soft mist inhaler or nebulizer. The pharmaceutical formulation for inhalation comprises caplacizumab.